KellyB.PendergrassMD

Oncology • Blue Springs, MO

Assistant Professor, Internal Medicine, University Kansas School of Medicine

Join to view full profile

Dr. Pendergrass is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Pendergrass' full profile

Already have an account?

Office
4881 NE Goodview Cir
Blue Springs, MO 64064
Phone+1 913-574-2350

Fax+1 913-574-2413

Education & Training

University of TennesseeResidency, Internal Medicine, 1975 - 1978
University of Kansas School of MedicineClass of 1975

Certifications & Licensure

KS State Medical License 1994 - 2025
LA State Medical License 2021 - 2022
MO State Medical License 1980 - 2021
MD State Medical License 1979 - 1983

Awards, Honors, & Recognition

Super Doctor SuperDoctors.com
Top MD Consumers Checkbook

Clinical Trials

Carboplatin With Either Paclitaxel Poliglumex or Paclitaxel in Treating Women With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer Start of enrollment: 2007 Aug 01
Terminated
Phase 3
Myelodysplastic Syndromes (MDS) Event Free Survival With Iron Chelation Therapy Study Start of enrollment: 2010 Mar 22
Completed
Phase 2
Study of 0.1% Uracil Topical Cream (UTC) for the Prevention of Hand-Foot Syndrome Start of enrollment: 2010 Apr 01
Completed
Phase 1, Phase 2
Phase 3 Trial in Squamous Non Small Cell Lung Cancer Subjects Comparing Ipilimumab Versus Placebo in Addition to Paclitaxel and Carboplatin Start of enrollment: 2011 Jan 16
Completed
Phase 3
Join now to see all

Publications & Presentations

PubMed

103 citations
A randomized trial of avatrombopag, an investigational thrombopoietin-receptor agonist, in persistent and chronic immune thrombocytopenia
James B. Bussel, David J. Kuter, Louis M. Aledort, Craig M. Kessler, Adam Cuker
Blood. 2014-06-19
136 citations
Randomized, Placebo-Controlled, Phase III Study of First-Line Oxaliplatin-Based Chemotherapy Plus PTK787/ZK 222584, an Oral Vascular Endothelial Growth Factor Receptor...
J. Randolph Hecht, Tanja Trarbach, John D. Hainsworth, Pierre Major, Elke Jäger
Journal of Clinical Oncology. 2011-05-20
437 citations
Results of the CONFIRM Phase III Trial Comparing Fulvestrant 250 mg With Fulvestrant 500 mg in Postmenopausal Women With Estrogen Receptor–Positive Advanced Breast Cancer
Angelo Di Leo, Guy Jerusalem, Lubos Petruzelka, Roberto Torres, Igor Bondarenko
Journal of Clinical Oncology. 2010-10-20

Professional Memberships

American Society of Clinical Oncology - ASCO
Member